RecruitingAlzheimer DiseaseDementia AlzheimersDementia
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
Eligible age
18–89 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This project's main goal is to use state-of-the-art passive sensing techniques to identify digital biomarkers that relate to bioenergetic changes in the brain due to nicotinamide riboside supplementation in those with mild cognitive impairment and mild Alzheimer's dementia.
Sponsor: Mclean Hospital
You may qualify if…
- ✓ Ability of the participant and/or his/her legally authorized representative to understand the purpose and risks of the study, to provide signed and dated informed consent, and to authorize the use of confidential health information.
- ✓ Ability to speak and read fluently in English
- ✓ 18-89 years old (inclusive)
- ✓ Normal or corrected to normal hearing and vision
- ✓ Meet clinical diagnostic criteria for MCI or Mild AD, according to the criteria outlined above
- ✓ Study partner available for duration of trial participation
- ✓ At least one copy of the APOE ε4 allele
- ✓ An aggregate risk score \> 4 according to the risk analysis method developed by Sabbagh et al. (2017)
You may not qualify if…
- ✕ Current serious or unstable medical or neurological condition that could affect cognitive functioning, as determined by study clinician
- ✕ Clinically unstable mood or anxiety disorder within 6 months prior to screening, as determined by study clinician
- ✕ Lifetime history of psychotic disorder (i.e. Schizophrenia, Schizoaffective Disorder), as determined by study clinician
- ✕ Diagnosis of a mitochondrial disorder
- ✕ Any MRI safety contraindications
- ✕ History of drug hypersensitivity or intolerance to NR
- ✕ Transient ischemic attack or stroke within 1 year prior to screening
- ✕ History of alcohol or substance abuse within prior year, as determined by study clinician and urine toxicology screen
Where it's recruiting
Massachusetts
Belmont
Source: ClinicalTrials.gov · NCT05245903 · last updated 2025-11-06